3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
25
Neoplasm Metastasis
5
Breast Neoplasms
5
Prostatic Neoplasms, Castration-Resistant
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostate Cancer Metastatic
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Preference
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
NSCLC Harboring NRG1 Fusion
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration Resistant Prostate Cancer
1
Metastatic Castrate-Resistant Prostate Cancer
1
Interventions
Cisplatin
3
Pemetrexed
2
Etoposide
2
pomalidomide
1
etoposide phosphate
1
enzalutamide
1
bemiparin
1
apalutamide
1
alvocidib
1
abiraterone
1
Radiation
1
RRx-001
1
Gemcitabine
1
GSK2879552
1
Depsipeptides
1
Carboplatin
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Small Cell
×
enzalutamide
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts